CereVasc

CereVasc is a medical device company dedicated to developing novel minimally invasive treatments for patients with neurological disorders. CereVasc is currently developing the eShunt™ system, designed to treat patients with communicating hydrocephalus, one of the most common neurological conditions affecting both children and adults. Current treatments for these patients require invasive neurosurgical procedures, which have significantly lower success rates compared to other neurosurgical interventions. The eShunt system has the potential to significantly improve patient outcomes and substantially reduce the overall surgical treatment costs associated with this life-threatening condition. CereVasc leverages new technologies in vascular and neural pathways to innovate less invasive, minimally invasive approaches to hydrocephalus treatment. The company has recently received approval from Argentina’s National Administration of Drugs, Food and Medical Devices (ANMAT) to conduct a clinical study titled “Endovascular Treatment of Hydrocephalus Using the eShunt System.”The eShunt system, developed by CereVasc, represents an effective solution to overcome the limitations of traditional treatment methods. The system, approximately 5 centimeters in length, consists of a cerebrospinal fluid shunt that can be implanted into blood vessels along with associated delivery components, achieving hydrocephalus treatment by placement at the base of the brain.CereVasc’s implantation procedure employs a minimally invasive approach—navigating the eShunt through the femoral vein at the patient’s groin until the device reaches its target location. This system effectively eliminates the invasiveness of hydrocephalus treatment and the need for general anesthesia, reducing hospital stays and postoperative pain management costs for patients.Additionally, the eShunt system’s design for vascular implantation and updates to related components significantly mitigate issues such as catheter blockage and over-drainage caused by shunt system failures.